Considerations When Developing Blood-Brain Barrier Crossing Drug Delivery Technology.

Area of Science:

• Neuroscience
• Biotechnology
• Pharmacology

Background:

• Central nervous system (CNS) drug delivery is hindered by biological barriers like the blood-brain barrier (BBB), immune responses, and peripheral clearance mechanisms.
• Existing BBB-crossing modalities offer valuable insights but require further optimization.
• Neurological and neurodegenerative disorders necessitate advanced therapeutic delivery strategies.

Purpose of the Study:

• To provide insights into developing and evaluating technologies for CNS drug delivery.
• To review biological barriers and clearance mechanisms impacting drug transport.
• To highlight engineering and scalability challenges for clinical translation.

Main Methods:

• Review of biological barriers (immune system, BBB components, peripheral clearance).
• Analysis of existing blood-brain barrier-crossing modalities and learnings.
• Discussion of "BBBomic" databases and in vivo validation requirements.
• Examination of manufacturing and scalability for clinical feasibility.

Main Results:

• Identification of multiple biological barriers to brain drug delivery.
• Evaluation of current BBB-crossing technologies and their limitations.
• Emphasis on the importance of "BBBomics" and robust validation studies.
• Highlighting manufacturing and scalability as critical for clinical translation.

Conclusions:

• Overcoming biological and engineering barriers is crucial for effective CNS drug delivery.
• Biotherapeutic and gene therapy applications require tailored delivery solutions.
• Successful clinical translation depends on addressing scalability and manufacturing challenges.